Company profile: AltPep
1.1 - Company Overview
Company description
- Provider of diagnostic and therapeutic solutions for amyloid diseases, including SOBA Diagnostics for early detection and SOBIN Therapeutics for early treatment by targeting toxic soluble oligomers; offerings also include anti-biofilm applications.
Products and services
- Anti-Biofilm Applications: Modular assemblies leveraging AltPep’s novel approach to deliver anti-biofilm applications, addressing biofilm challenges informed by amyloid-related research contexts
- SOBA Diagnostics: Oligomer-specific diagnostic tool targeting toxic soluble oligomers for early detection of amyloid diseases, enabling early identification via oligomer recognition
- SOBIN Therapeutics: Custom-engineered therapeutics targeting toxic soluble oligomers for early treatment of amyloid diseases, delivering oligomer-directed intervention at early disease stages
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AltPep
Baergic Bio
HQ: United States
Website
- Description: Provider of novel therapeutics for the treatment of central nervous system (CNS) disorders, developed and commercialised by a biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Baergic Bio company profile →
Allay Therapeutics
HQ: United States
Website
- Description: Provider of analgesic products for post-surgical pain management and recuperation, including ATX-101, which delivers controlled-release bupivacaine at the surgical site to provide weeks of pain relief after total knee replacement. Offers a proprietary technology platform combining non-opioid analgesics and biopolymers to create dissolvable candidates for localized, extended pain relief.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allay Therapeutics company profile →
Arrivo BioVentures
HQ: United States
Website
- Description: Provider of pharmaceutical development focused on identifying biologics and small molecules to improve patient care, including RABI-767, a small-molecule lipase inhibitor for severe acute pancreatitis aiming to prevent systemic toxicity and organ failure, and SP-624, a novel small molecule in Phase 2 for major depressive disorder that targets neuronal connectivity and function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arrivo BioVentures company profile →
Aelis Farma
HQ: France
Website
- Description: Provider of signaling-specific therapeutics targeting GPCRs, notably the CB1 receptor, including AEF0117 for cannabis-related disorders, AEF0217 for cognitive deficits (initially Down syndrome, with potential for Fragile X syndrome and aging), and CB1-SSi inhibitors that selectively inhibit pathological CB1 hyperactivity without affecting normal brain functions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aelis Farma company profile →
ADx Neurosciences
HQ: Belgium
Website
- Description: Provider of proprietary biomarker assays and antibody solutions for neurodegenerative diseases, enabling early detection of Alzheimer’s, Parkinson’s and traumatic brain injury. Delivers custom and monoclonal antibodies (Amyloid-beta, Tau, Synuclein), pharma and IVD solutions from antibody to qualified assay and automated kits, and co-develops commercial immunoassays for clinical and drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADx Neurosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AltPep
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AltPep
2.2 - Growth funds investing in similar companies to AltPep
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AltPep
4.2 - Public trading comparable groups for AltPep
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →